2,731 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 2nd quarter, Holdings Channel.com reports. The firm bought 2,731 shares of the medical research company’s stock, valued at approximately $1,369,000.

Several other institutional investors and hedge funds have also modified their holdings of TMO. Elyxium Wealth LLC grew its position in shares of Thermo Fisher Scientific by 1.9% during the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock valued at $613,000 after acquiring an additional 20 shares during the period. Revolve Wealth Partners LLC lifted its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. grew its holdings in Thermo Fisher Scientific by 0.7% during the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock valued at $1,436,000 after purchasing an additional 20 shares during the period. Confluence Wealth Services Inc. increased its position in Thermo Fisher Scientific by 0.5% in the fourth quarter. Confluence Wealth Services Inc. now owns 4,292 shares of the medical research company’s stock worth $2,487,000 after buying an additional 22 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Thermo Fisher Scientific by 0.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,985 shares of the medical research company’s stock worth $2,311,000 after buying an additional 22 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Robert W. Baird lowered their target price on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Royal Bank Of Canada raised their price target on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a report on Friday, July 24th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $628.24 on Friday. The firm has a market cap of $232.29 billion, a price-to-earnings ratio of 33.79, a P/E/G ratio of 2.50 and a beta of 0.85. The firm has a fifty day moving average price of $539.33 and a 200 day moving average price of $508.86. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter last year, the business posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president directly owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 4,608 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $586.12, for a total transaction of $2,700,840.96. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,493 shares of company stock valued at $37,657,681 over the last quarter. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.